Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516223 | PMC |
| http://dx.doi.org/10.1089/thy.2022.0707 | DOI Listing |
Publication Analysis
Top Keywords
sel-i-metry phase
4
phase trial
4
trial resensitization
4
resensitization advanced
4
advanced iodine
4
iodine refractory
4
refractory differentiated
4
differentiated thyroid
4
thyroid cancer
4
cancer radioiodine
4
Similar Publications
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.
Thyroid
September 2023
Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
Background: Thyroid cancer is the most common endocrine malignancy. Some advanced disease is, or becomes, resistant to radioactive iodine therapy (refractory disease); this holds poor prognosis of 10% 10-year overall survival. Whilst Sorafenib and Lenvatinib are now licenced for the treatment of progressive iodine refractory thyroid cancer, these treatments require continuing treatment and can be associated with significant toxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!